-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
The -X- _ O
2009 -X- _ O
influenza -X- _ O
pandemic -X- _ O
was -X- _ O
caused -X- _ O
by -X- _ O
the -X- _ O
A -X- _ O
/ -X- _ O
H1N1pdm09 -X- _ O
virus -X- _ O
, -X- _ O
which -X- _ O
was -X- _ O
subsequently -X- _ O
included -X- _ O
in -X- _ O
the -X- _ O
seasonal -X- _ O
vaccine -X- _ O
, -X- _ O
up -X- _ O
to -X- _ O
2016 -X- _ O
/ -X- _ O
2017 -X- _ O
, -X- _ O
as -X- _ O
the -X- _ O
A -X- _ O
/ -X- _ O
H1N1 -X- _ O
strain. -X- _ O
This -X- _ O
provided -X- _ O
a -X- _ O
unique -X- _ O
opportunity -X- _ O
to -X- _ O
investigate -X- _ O
the -X- _ O
antibody -X- _ O
response -X- _ O
to -X- _ O
H1N1pdm09 -X- _ O
over -X- _ O
time. -X- _ O
METHODS -X- _ O
: -X- _ O
Healthcare -X- _ B-Patient
workers -X- _ I-Patient
( -X- _ I-Patient
HCWs -X- _ I-Patient
) -X- _ I-Patient
were -X- _ O
immunized -X- _ B-Intervention
with -X- _ I-Intervention
the -X- _ I-Intervention
AS03-adjuvanted -X- _ I-Intervention
H1N1pdm09 -X- _ I-Intervention
vaccine -X- _ I-Intervention
in -X- _ I-Intervention
2009 -X- _ I-Intervention
( -X- _ I-Intervention
N -X- _ I-Intervention
= -X- _ I-Intervention
250 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
and -X- _ O
subsequently -X- _ O
vaccinated -X- _ O
with -X- _ O
seasonal -X- _ O
vaccines -X- _ O
containing -X- _ O
H1N1pdm09 -X- _ O
for -X- _ O
4 -X- _ O
seasons -X- _ O
( -X- _ O
repeated -X- _ O
group -X- _ O
) -X- _ O
, -X- _ O
< -X- _ O
4 -X- _ O
seasons -X- _ O
( -X- _ O
occasional -X- _ O
group -X- _ O
) -X- _ O
, -X- _ O
or -X- _ O
no -X- _ O
seasons -X- _ O
( -X- _ O
single -X- _ O
group -X- _ O
) -X- _ O
. -X- _ O
Blood -X- _ O
samples -X- _ O
were -X- _ O
collected -X- _ O
pre -X- _ O
and -X- _ O
at -X- _ O
21 -X- _ O
days -X- _ O
and -X- _ O
3 -X- _ O
, -X- _ O
6 -X- _ O
, -X- _ O
and -X- _ O
12 -X- _ O
months -X- _ O
after -X- _ O
each -X- _ O
vaccination -X- _ O
, -X- _ O
or -X- _ O
annually -X- _ O
( -X- _ O
pre-season -X- _ O
) -X- _ O
from -X- _ O
2010 -X- _ O
in -X- _ O
the -X- _ O
single -X- _ O
group. -X- _ O
The -X- _ O
H1N1pdm09- -X- _ O
specific -X- _ O
antibodies -X- _ O
were -X- _ O
measured -X- _ O
by -X- _ O
the -X- _ O
hemagglutination -X- _ O
inhibition -X- _ O
( -X- _ O
HI -X- _ O
) -X- _ O
assay. -X- _ O
RESULTS -X- _ O
: -X- _ O
Pandemic -X- _ B-Outcome
vaccination -X- _ I-Outcome
robustly -X- _ I-Outcome
induced -X- _ I-Outcome
HI -X- _ I-Outcome
antibodies -X- _ I-Outcome
that -X- _ I-Outcome
persisted -X- _ I-Outcome
above -X- _ I-Outcome
the -X- _ I-Outcome
50 -X- _ I-Outcome
% -X- _ I-Outcome
protective -X- _ I-Outcome
threshold -X- _ I-Outcome
( -X- _ I-Outcome
HI -X- _ I-Outcome
titers -X- _ I-Outcome
≥ -X- _ I-Outcome
40 -X- _ I-Outcome
) -X- _ I-Outcome
over -X- _ I-Outcome
12 -X- _ I-Outcome
months -X- _ I-Outcome
post-vaccination. -X- _ I-Outcome
Previous -X- _ I-Outcome
seasonal -X- _ I-Outcome
vaccination -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
duration -X- _ I-Outcome
of -X- _ I-Outcome
adverse -X- _ I-Outcome
events -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
pandemic -X- _ I-Outcome
vaccination -X- _ I-Outcome
influenced -X- _ I-Outcome
the -X- _ I-Outcome
decision -X- _ I-Outcome
to -X- _ I-Outcome
vaccinate -X- _ I-Outcome
in -X- _ I-Outcome
subsequent -X- _ I-Outcome
seasons. -X- _ I-Outcome
During -X- _ I-Outcome
2010 -X- _ I-Outcome
/ -X- _ I-Outcome
2011–2013 -X- _ I-Outcome
/ -X- _ I-Outcome
2014 -X- _ I-Outcome
, -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
boosted -X- _ I-Outcome
after -X- _ I-Outcome
each -X- _ I-Outcome
seasonal -X- _ I-Outcome
vaccination -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
difference -X- _ I-Outcome
was -X- _ I-Outcome
observed -X- _ I-Outcome
between -X- _ I-Outcome
the -X- _ I-Outcome
repeated -X- _ I-Outcome
and -X- _ I-Outcome
occasional -X- _ I-Outcome
groups. -X- _ I-Outcome
In -X- _ I-Outcome
the -X- _ I-Outcome
single -X- _ I-Outcome
group -X- _ I-Outcome
without -X- _ I-Outcome
seasonal -X- _ I-Outcome
vaccination -X- _ I-Outcome
, -X- _ I-Outcome
32 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
HCWs -X- _ I-Outcome
seroconverted -X- _ I-Outcome
( -X- _ I-Outcome
≥4-fold -X- _ I-Outcome
increase -X- _ I-Outcome
in -X- _ I-Outcome
HI -X- _ I-Outcome
titers -X- _ I-Outcome
) -X- _ I-Outcome
during -X- _ I-Outcome
the -X- _ I-Outcome
4 -X- _ I-Outcome
subsequent -X- _ I-Outcome
years -X- _ I-Outcome
, -X- _ I-Outcome
most -X- _ I-Outcome
of -X- _ I-Outcome
whom -X- _ I-Outcome
had -X- _ I-Outcome
HI -X- _ I-Outcome
titers -X- _ I-Outcome
< -X- _ I-Outcome
40 -X- _ I-Outcome
prior -X- _ I-Outcome
to -X- _ I-Outcome
seroconversion. -X- _ I-Outcome
When -X- _ I-Outcome
excluding -X- _ I-Outcome
these -X- _ I-Outcome
seroconverted -X- _ I-Outcome
HCWs -X- _ I-Outcome
, -X- _ I-Outcome
HI -X- _ I-Outcome
titers -X- _ I-Outcome
gradually -X- _ I-Outcome
declined -X- _ I-Outcome
from -X- _ I-Outcome
12 -X- _ I-Outcome
to -X- _ I-Outcome
60 -X- _ I-Outcome
months -X- _ I-Outcome
post–pandemic -X- _ I-Outcome
vaccination. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Pandemic -X- _ B-Outcome
vaccination -X- _ I-Outcome
elicited -X- _ I-Outcome
durable -X- _ I-Outcome
antibodies -X- _ I-Outcome
, -X- _ I-Outcome
supporting -X- _ I-Outcome
the -X- _ I-Outcome
incorporation -X- _ I-Outcome
of -X- _ I-Outcome
adjuvant. -X- _ I-Outcome
Our -X- _ I-Outcome
findings -X- _ I-Outcome
support -X- _ I-Outcome
the -X- _ I-Outcome
current -X- _ I-Outcome
recommendation -X- _ I-Outcome
of -X- _ I-Outcome
annual -X- _ I-Outcome
influenza -X- _ I-Outcome
vaccination -X- _ I-Outcome
in -X- _ I-Outcome
HCWs. -X- _ I-Outcome
CLINICAL -X- _ O
TRIALS -X- _ O
REGISTRATION -X- _ O
: -X- _ O
NCT01003288 -X- _ O
. -X- _ O

